AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.
GlobalData on MSN8d
EC authorises Celltrion’s Avtozma for multiple indicationsCelltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...
Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...
Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...
South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...
Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...
Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab). Avtozma ® has been ...
South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback